Skip to main content

Table 1 Patient demographics

From: Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database

Characteristics N (%)
Age group (years)
 < 12 2 (0.10)
 ≥ 12 to < 20 5 (0.20)
 ≥ 20 to < 40 376 (16.10)
 ≥ 40 to < 60 1162 (49.90)
 ≥ 60 784 (33.70)
Gender
 Male 1570 (67.40)
 Female 583 (25.00)
 Gender not disclosed 176 (7.60)
Comorbidities
 Diabetes 679 (29.69)
 Hypertension 465 (20.33)
 Cardiac disease 145 (6.34)
 Lung disease 100 (4.37)
Need for oxygen supplementation
 SLFO 1483 (65.27)
 HFO 433 (19.06)
 NIV 273 (12.02)
 MV 80 (3.52)
Concomitant medications
 Antibiotics 702 (64.90)
 Steroids 518 (47.90)
 Anticoagulants 345 (31.90)
 Vitamin C 246 (22.80)
 Zinc 124 (11.50)
  1. SLFO standard low-flow oxygen, HFO high-flow oxygen, NIV non-invasive ventilation, MV mechanical ventilation